No Data
No Data
Keymed Biosciences Inc. (HKG:2162) Just Reported, And Analysts Assigned A HK$69.56 Price Target
Shareholders might have noticed that Keymed Biosciences Inc. (HKG:2162) filed its annual result this time last week. The early response was not positive, with shares down 6.6% to HK$33.90 in the past
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 7% in the intraday period, annual revenue increased 2.5 times, and CM310 is expected to be approved for listing within the year
Conoa-B (02162) rose more than 7% in the intraday period. As of press release, it was up 5.11% to HK$3.39, with a turnover of HK$396.561 million.
Retail Investors Among Keymed Biosciences Inc.'s (HKG:2162) Largest Stockholders and Were Hit After Last Week's 14% Price Drop
Key Insights Significant control over Keymed Biosciences by retail investors implies that the general public has more power to influence management and governance-related decisions The top 8 shareho
KeyMed Biosciences' Attributable Loss Widens in 2023
KeyMed Biosciences (HKG:2162) widened its attributable loss to owners for the year ended Dec. 31, 2023, to 359.3 million yuan, compared with 308.1 million yuan in the year-ago period, according to a f
Conoah Announces 2023 Results: Deepening Differential Innovation and Ready to Start Commercialization
The drug marketing license application (NDA) for the treatment of moderate to severe atopic dermatitis in adults (CM310), a core product in the field of autoimmunity, has been accepted by the China Drug Administration and included in the priority review and approval process; the phase III clinical study data on the treatment of chronic sinusitis with nasal polyps were positive, and the common main endpoints were fully met. It is expected that NDA for this indication will be declared in 2024; at the same time, the use of sipcibimab for the treatment of moderate and severe atopic dermatitis in adolescents will be launched and promoted separately Seasonal allergic rhinitis Phase III clinical study; in situ
Press Release: Keymed Biosciences Announces 2023 Annual Results and Business Updates
Keymed Biosciences Announces 2023 Annual Results and Business Updates PR Newswire CHENGDU, China, March 26, 2024 -- Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the tr
No Data